Millipede 088 Post-Marketing Study

  • Research type

    Research Study

  • Full title

    Post Marketing Study to Evaluate Millipede 088 Effectiveness for Clot Retrieval in Acute Ischemic Stroke.

  • IRAS ID

    309110

  • Contact name

    Hazel Kilkelly

  • Contact email

    hazel@perfuze.com

  • Sponsor organisation

    Perfuze Ltd

  • Duration of Study in the UK

    1 years, 1 months, 28 days

  • Research summary

    This study is being conducted to gather information about a medical device used for treating patients that are having a stroke. The device being assessed in this study is called the Millipede 088. It is a tube, called a catheter, that sucks clots from the brain in patients that are having a stroke. The study is being carried out to assess how effectively and safely the device removes clots from the blood vessels in the brain.

    This device has received CE mark approval, meaning it meets the safety and performance requirements of the relevant European legislation. Millipede 088 medical device is currently available for market use in the European Union (EU), European Economic Area (EEA) and the United Kingdom (UK).

    Up to 100 subjects may be recruited at up to 8 investigation sites across the UK and Germany. Subject follow-ups will be conducted at Day 0, 24 hours post-procedure, Day 7 post-procedure or hospital discharge/transfer (whichever occurs soonest) if performed per institutional standard practice and Day 90 post-procedure. An mRS assessment may be conducted with the participant by a member of the research team at 90 days post-procedure if this assessment has not been completed as part of the participants standard of care. The mRS assessment will be conducted via telephone to minimize the burden on the participant. Apart from the mRS assessment at 90 days post-procedure, all other data collected as part of this post-market clinical follow-up study is collected as part of the participant's standard of care, and there are no further study specific assessments to be completed by participants.

  • REC name

    Wales REC 1

  • REC reference

    22/WA/0059

  • Date of REC Opinion

    14 Apr 2022

  • REC opinion

    Further Information Favourable Opinion